Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Nvidia's positions in these companies were relatively small at the end of the third quarter of 2025, but the chipmaker has spent recent years building a portfolio of AI‑related investments across ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are trying to figure out whether Recursion Pharmaceuticals is ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...